FSH as a biomarker of bone strength in younger postmenopausal women

描述(由申请人提供)： 美国国立卫生研究院2000年共识小组将骨质疏松症描述为一种骨骼疾病，其特征是骨骼强度下降，容易增加骨折的风险。这项拟议研究的长期目标是了解血清卵泡刺激素(FSH)是否可以用作临床上识别骨强度两个可测量成分显著下降的绝经后年轻女性的生物标志物：面骨密度(通过双能X射线吸收测量仪测量)和骨质量(通过外周定量计算机断层扫描(PQCT)评估)。在动物模型和对绝经前和围绝经期妇女的队列研究中，已经报道了FSH相关变量和低骨密度之间的关联；然而，到目前为止，还没有研究验证FSH和骨质量之间可能的关系。在一项对16名年龄在50岁到之间的绝经后妇女的研究中，我们发现乘性变量促卵泡激素和桡骨远端的骨密度之间存在中等的和统计上显著的未调整相关性。在拟议的项目中，我们还将测试FSH相关变量与前臂远端骨质量的pQCT测量之间的相关性，考虑到激素对骨的影响。具体目的：1)在初级保健诊所招募的111名年龄在50岁至之间的绝经后妇女的横断面研究中，评估血清FSH与：a)骨质量、b)骨密度、c)骨转换的关系；2)检验FSH是否独立地与骨质量和桡骨远端骨密度相关，并调整其他激素因素。自2005年2月以来，我们的多学科研究团队在美国国立卫生研究院资助的北卡罗来纳大学综合临床研究中心进行了一项与骨骼相关的生物标记物的研究。我们将扩展这项研究，以包括新的激素措施和为拟议的项目进行的pQCT骨成像的专门分析。结果将表明，未来的研究是否应该测试FSH的诊断准确性，以确定高危的年轻绝经后妇女，这些妇女可以在常规骨质疏松症筛查的推荐年龄之前从预防性干预中受益。项目简介骨质疏松症是一种骨强度低的情况，导致老年妇女骨折相关的高发病率和死亡率。这项研究将探讨血清FSH作为年轻绝经后妇女骨强度低下的生物标志物应用于临床的可能性。

DESCRIPTION (provided by applicant): The NIH Consensus Panel 2000 described osteoporosis as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. The long-term objective of the proposed study is to learn whether serum follicle stimulating hormone (FSH) could be used clinically as a biomarker to identify younger postmenopausal women with significant declines in the two measurable components of bone strength: areal bone mineral density (measured by dual-energy x-ray absorptiometry) and bone quality (assessed by peripheral quantitative computed tomography [pQCT]). Associations between FSH-related variables and low bone density have been reported in animal models and a cohort study of pre- and perimenopausal women; however, no study to date has tested for a possible relationship between FSH and bone quality. In a study of 16 postmenopausal women aged 50 to 64 years, we found a moderate and statistically significant unadjusted correlation between the multiplicative variable FSH-years and areal bone density in the distal radius. In the proposed project, we will also test for correlations between FSH-related variables and pQCT measures of bone quality in the distal forearm, accounting for hormonal influences on bone. Specific Aims: 1) In a cross-sectional study of 111 postmenopausal women aged 50 to 64 years recruited from primary care clinics, evaluate the relationship between serum FSH and: a) bone quality, b) bone mineral density, c) bone turnover; 2) Test whether FSH is independently associated with bone quality and bone mineral density in the distal radius, adjusted for other hormonal factors. Our multidisciplinary research team has conducted a study of bone- related biomarkers in the NIH-funded General Clinical Research Center at the University of North Carolina since February 2005. We will extend this study to include new hormonal measures and specialized analysis of pQCT imaging of bone for the proposed project. Results will show whether future studies should test the diagnostic accuracy of FSH to identify high-risk younger postmenopausal women who could benefit from preventive interventions before the recommended age for routine osteoporosis screening. PROJECT NARRATIVE Osteoporosis is a condition of low bone strength that leads to high fracture-related morbidity and mortality in elderly women. This study will examine the potential for serum FSH to be used clinically as a biomarker of low bone strength in younger postmenopausal women.